Center for Infectious Diseases and Vaccinology at Biodesign Institute and School of Life Sciences, Arizona State University, Tempe, Arizona 85287-5401, USA.
Infect Immun. 2010 Jun;78(6):2529-43. doi: 10.1128/IAI.00005-10. Epub 2010 Mar 22.
A balanced-lethal plasmid expression system that switches from low-copy-number to runaway-like high-copy-number replication (pYA4534) was constructed for the regulated delayed in vivo synthesis of heterologous antigens by vaccine strains. This is an antibiotic resistance-free maintenance system containing the asdA gene (essential for peptidoglycan synthesis) as a selectable marker to complement the lethal chromosomal DeltaasdA allele in live recombinant attenuated Salmonella vaccines (RASVs) such as Salmonella enterica serovar Typhimurium strain chi9447. pYA4534 harbors two origins of replication, pSC101 and pUC (low and high copy numbers, respectively). The pUC replication origin is controlled by a genetic switch formed by the operator/promoter of the P22 cro gene (O/P(cro)) (P(R)), which is negatively regulated by an arabinose-inducible P22 c2 gene located on both the plasmid and the chromosome (araC P(BAD) c2). The absence of arabinose, which is unavailable in vivo, triggers replication to a high-copy-number plasmid state. To validate these vector attributes, the Yersinia pestis virulence antigen LcrV was used to develop a vaccine against plague. An lcrV sequence encoding amino acids 131 to 326 (LcrV196) was optimized for expression in Salmonella, flanked with nucleotide sequences encoding the signal peptide (SS) and the carboxy-terminal domain (CT) of beta-lactamase, and cloned into pYA4534 under the control of the P(trc) promoter to generate plasmid pYA4535. Our results indicate that the live Salmonella vaccine strain chi9447 harboring pYA4535 efficiently stimulated a mixed Th1/Th2 immune response that protected mice against lethal challenge with Y. pestis strain CO92 introduced through either the intranasal or subcutaneous route.
构建了一种平衡致死质粒表达系统,该系统可从低拷贝数转变为类似失控的高拷贝数复制(pYA4534),用于通过疫苗株调节异源抗原的体内延迟合成。这是一个不含抗生素抗性的维持系统,包含 asdA 基因(肽聚糖合成所必需)作为选择标记,以补充活重组减毒沙门氏菌疫苗(RASV)中致死性染色体 DeltaasdA 等位基因,如鼠伤寒沙门氏菌血清型 Chi9447。pYA4534 含有两个复制起点,pSC101 和 pUC(低拷贝数和高拷贝数)。pUC 复制起点受 P22 cro 基因的操纵子/启动子(O/P(cro))(P(R))形成的遗传开关控制,该开关受位于质粒和染色体上的阿拉伯糖诱导型 P22 c2 基因(araC P(BAD) c2)的负调控。体内不存在阿拉伯糖会触发复制到高拷贝数质粒状态。为了验证这些载体属性,使用鼠疫耶尔森氏菌毒力抗原 LcrV 开发了一种抗鼠疫疫苗。编码氨基酸 131 至 326(LcrV196)的 lcrV 序列经过优化,可在沙门氏菌中表达,两端为编码信号肽(SS)和β-内酰胺酶羧基末端结构域(CT)的核苷酸序列,并在 P(trc)启动子的控制下克隆到 pYA4534 中,生成质粒 pYA4535。我们的结果表明,携带 pYA4535 的活沙门氏菌疫苗株 chi9447 能够有效地刺激混合 Th1/Th2 免疫反应,保护小鼠免受通过鼻内或皮下途径引入的鼠疫耶尔森氏菌菌株 CO92 的致死性挑战。